The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold ... enthusiasm about the progress of this mechanism of action. Positive outcomes from clinical trials ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in recent months. According to ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The use of Dupixent in AD has set a high benchmark ... pharmaceutical companies are investigating agents with different mechanisms of action to provide alternatives to the current standard of ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

“Having Dupixent as the gold standard for AD ... GlobalData sharing their excitement about the progress of anti-OX40L mechanism of action. Overall, the positive outcomes from the clinical ...